Catalog No.
Product Name
Application
Product Information
Citations
-
IRAK4 PROTAC Degrader
PROTAC IRAK4 degrader-13 is a selective IRAK4-directed PROTAC degrader that effectively targets IRAK4 with DC50 values of 0.86 nM and 1.1 nM in monocytes and lymphocytes, respectively. This compound significantly activates TIR signaling and reduces the expression of proinflammatory cytokines in an Imiquimod-induced psoriasis mouse model. PROTAC IRAK4 degrader-13 is applicable in research focused on TLR- and IL-1R-driven inflammatory diseases, including hidradenitis suppurativa and atopic dermatitis. -
IRAK4 Inhibitor
BMS-986126 is a potent and selective inhibitor of IRAK4, with an IC50 value of 5.3 nM. It effectively disrupts MyD88-dependent signaling pathways, thereby attenuating inflammatory responses associated with autoimmune conditions. In preclinical studies, BMS-986126 has demonstrated significant efficacy in murine models of lupus, including MRL/lpr and NZB/NZW strains. This compound is valuable for research applications related to systemic lupus erythematosus (SLE) and other autoimmune diseases. -
IRAK PROTAC Degradant
APH02174 is a highly selective IRAK4 PROTAC degrader that exhibits an impressive DC50 value of 4.01 nM in THP-1 cells. By effectively inhibiting the release of IL-6, APH02174 serves to block inflammatory signaling pathways. This compound is valuable for research into various inflammatory conditions, including psoriasis vulgaris and rheumatoid arthritis. -
c-Kit Receptor Modulator
c-Kit Receptor modulator-1 is a selective modulator of the c-Kit receptor, primarily involved in cell signaling pathways associated with hematopoiesis and mast cell function. This compound exhibits potent activity against malignancies such as canine mastocytoma, human gastrointestinal stromal tumors, and small cell lung cancer. It is a valuable tool for research focused on tumor biology and therapeutic interventions targeting c-Kit signaling pathways. -
C-Kit Inhibitor
c-Kit-IN-12 is a potent inhibitor of the c-Kit receptor with an IC50 value of less than 10 nM in various KIT mutant cell lines, including BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, and EX11 DEL/V654A. This compound is valuable for investigating c-Kit-related pathologies, particularly in cancer research. Its specificity and efficacy make it a useful tool for elucidating the role of c-Kit in oncogenic processes and for exploring potential therapeutic strategies. -
C-Kit Inhibitor
(S)-c-Kit-IN-12 is a potent c-Kit inhibitor, exhibiting an IC50 value of less than 10 nM across four different KIT mutant cell models, including BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, and EX11 DEL/V654A. This compound is suitable for investigating c-Kit-related diseases, particularly in cancer research applications, where dysregulation of c-Kit signaling is implicated. -
CSF-1R Inhibitor
Sotuletinib hydrochloride is a potent and selective inhibitor of the CSF-1R (c-Fms) with an IC50 value of 1 nM, demonstrating over 1,000-fold selectivity against related receptor tyrosine kinases. This orally bioavailable and brain-penetrant compound is utilized in research focused on microglia depletion, tumor biology, and central nervous system-related diseases, making it a valuable tool for advancing understanding in these areas. -
CSF1R Inhibitor
SYHA1813 is an inhibitor of the colony-stimulating factor 1 receptor (CSF1R) that demonstrates potent antitumor activity, particularly in glioblastoma (GBM). By targeting CSF1R, SYHA1813 modulates the tumor microenvironment and affects immune cell infiltration, making it a valuable tool for studying tumor progression and therapeutic resistance. This compound can be utilized in preclinical research to explore its efficacy in cancer treatment strategies. -
CSF1R Inhibitor
Enrupatinib is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) with potent oral bioavailability and central nervous system (CNS) penetration. It effectively inhibits macrophage proliferation and osteoclast differentiation in vitro, thereby mitigating neuroinflammation and preserving neuronal integrity in Alzheimer's disease models. Enrupatinib has demonstrated the ability to reduce disease-associated microglia gene expression and enhance cognitive function in 5xFAD and J20 mouse models. Additionally, it attenuates tumor-associated macrophage infiltration and improves the antitumor efficacy of anti-PD-1 antibodies in preclinical models of colorectal and breast cancer, making it a valuable tool for research in these areas. -
CSF1R Inhibitor
AZ683 is a selective inhibitor of the colony stimulating factor 1 receptor (CSF1R), with a high binding affinity (Ki=8 nM; IC50=6 nM). This compound demonstrates good oral bioavailability, making it suitable for in vivo studies. Additionally, [11C]AZ683 serves as a positron emission tomography (PET) radiotracer for visualizing CSF1R activity, enabling insights into its role in various biological processes and diseases. This compound is valuable for research applications focused on immune modulation and tumor microenvironment studies. -
CSF1R Inhibitor
CSF1R-IN-12 is a potent inhibitor of colony stimulating factor 1 receptor (CSF1R), which plays a crucial role in regulating bone marrow progenitor cells, monocytes, macrophages, and giant cells. By targeting CSF1R, this compound exhibits significant potential for cancer research, particularly in studies focused on the modulation of macrophage activity and tumor microenvironment interaction. CSF1R-IN-12 can aid in elucidating the role of CSF1R in various malignancies and in the development of novel therapeutic strategies. -
CSF1R Inhibitor
CSF1R-IN-24 is an orally active inhibitor of the colony-stimulating factor 1 receptor (CSF1R). This compound significantly reduces the survival of human induced pluripotent stem cell-derived microglia (hiPSC-MG), making it a valuable tool for studying microglial biology and potential therapeutic applications in neuroinflammatory conditions. Researchers can utilize CSF1R-IN-24 to investigate the role of microglia in various disease models and to explore new treatment strategies targeting the CSF1R pathway. -
CSF-1R Inhibitor
CSF1R-IN-3 is a potent and orally bioavailable inhibitor of the colony-stimulating factor 1 receptor (CSF-1R), with an IC50 of 2.1 nM. This compound exhibits significant antiproliferative activity against colorectal cancer cells by inhibiting the progression of the disease through the suppression of macrophage migration. Additionally, CSF1R-IN-3 facilitates the reprogramming of M2-like macrophages into the M1 phenotype, thereby enhancing antitumor immunity. This compound serves as a valuable tool for research in cancer immunology and macrophage biology. -
CSF1R/Mer/Axl Inhibitor
Adrixetinib is a potent triple inhibitor targeting CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM respectively. This compound serves as an effective immune modulator by remodeling the tumor microenvironment, enhancing the presence of M1 macrophages and CD8⁺ T cells while reducing M2 macrophages and myeloid-derived suppressor cells (MDSCs). Additionally, Adrixetinib increases the expression of MHC class I and E-cadherin in tumor cells, demonstrating significant antitumor efficacy in syngeneic mouse models. It is relevant for research involving breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma. -
CSF1R Inhibitor
BPR1R024 mesylate is a selective inhibitor of the colony-stimulating factor-1 receptor (CSF1R), demonstrating potent inhibitory activity with an IC50 value of 0.53 nM. This compound is orally active and serves as a valuable tool for research in immuno-oncology, facilitating the exploration of CSF1R's role in tumor microenvironments and immune system modulation. BPR1R024 mesylate's targeted action enables detailed studies of its effects on macrophage biology and associated therapeutic strategies. -
PI3Kδ/CSF1R Inhibitor
JMC14 is a selective PI3Kδ and CSF1R inhibitor, exhibiting IC50 values of 12 nM and 143 nM, respectively. This compound preferentially disrupts PI3Kδ-mediated signaling within cells, demonstrating significant antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and in vivo models. JMC14 is an important tool for research into antitumor immunity and the mechanisms of cancer progression. -
CSF1-R Inhibitor
Sotuletinib dihydrochloride is a highly selective and potent inhibitor of the colony-stimulating factor 1 receptor (CSF1-R or c-Fms), exhibiting an IC50 of 1 nM and over 1,000-fold selectivity against closely related receptor tyrosine kinases. This compound is effective for the depletion of microglia and is valuable in research applications related to tumors and central nervous system (CNS) disorders. Its oral bioavailability and ability to penetrate the blood-brain barrier enhance its utility in neuropharmacological studies. -
Axl/Mer/CSF1R Inhibitor
Axl/Mer/CSF1R-IN-2 is a selective inhibitor targeting Axl, Mer, and CSF1R receptors. This compound demonstrates potent inhibition of these receptor kinases, which are implicated in various cancer types and immune response regulation. It is suitable for research applications focusing on tumor microenvironment modulation, immune checkpoint interactions, and potential therapeutic strategies in oncological studies. -
CSF1R Inhibitor
IACS-9439 is a potent and selective inhibitor of the colony-stimulating factor 1 receptor (CSF1R) with a Ki value of 1 nM. This orally active compound demonstrates significant potential in cancer research, particularly for the treatment of advanced solid tumors. It enables investigation into the role of CSF1R in tumor microenvironments and immune modulation. -
CSF1R Inhibitor
CSF1R-IN-5 is a potent inhibitor of the colony-stimulating factor 1 receptor (CSF1R), which plays a critical role in the survival and differentiation of macrophages. By targeting the CSF-1/CSF-1R signaling pathway, CSF1R-IN-5 modulates the interaction between tumor-associated macrophages (TAMs) and glioma cells, influencing the exchange of inflammatory mediators. This compound is useful for research applications in cancer biology, particularly in studies investigating the tumor microenvironment and macrophage function in oncogenesis. -
CSF-1R Inhibitor
CSF1R-IN-7 is a selective inhibitor of Colony Stimulating Factor 1 Receptor (CSF-1R). This compound demonstrates potential in modulating microglial activation, making it a valuable tool for research in neuroinflammatory conditions such as Alzheimer’s disease. It is particularly useful for studying the role of CSF-1R in the pathology and progression of neurodegenerative disorders. -
CSF-1R Inhibitor
CSF1R-IN-9 is a selective inhibitor of the colony-stimulating factor 1 receptor (CSF-1R), demonstrating an IC50 of 0.028 μM. This compound effectively disrupts CSF-1R signaling, making it valuable for research on macrophage biology and inflammation. CSF1R-IN-9 can be utilized in investigating therapeutic strategies for conditions such as cancer and autoimmune diseases. -
CSF1R Inhibitor
CSF1R-IN-14 is a potent inhibitor of the colony stimulating factor 1 receptor (CSF1R). As an isoindolinone derivative, it effectively modulates the activity of CSF-1, a key growth factor regulating the development and function of monocytes and macrophages. This compound holds potential for advancing research in cancer biology and studying immune responses associated with tumor progression. -
CSF1R Inhibitor
CSF1R-IN-23 is a selective inhibitor of colony-stimulating factor-1 receptor (CSF1R) with an IC50 of 36.1 nM. This compound demonstrates significant neuroinflammatory activity in mouse models, making it a valuable tool for studying neuroinflammation and related pathways. Additionally, CSF1R-IN-23 is permeable to the blood-brain barrier (BBB), facilitating its use in neurological research applications. -
CSF1R Inhibitor
CSF1R-IN-4 is a selective inhibitor of the colony-stimulating factor 1 receptor (CSF1R). This compound plays a critical role in modulating macrophage survival and differentiation by targeting the CSF-1/CSF-1R signaling pathway. CSF1R-IN-4 has been shown to influence the interaction between tumor-associated macrophages (TAMs) and glioma cells, making it a valuable tool for cancer research. Its potential applications include studying the tumor microenvironment and the immune response in various malignancies. -
CSF1R Inhibitor
CSF1R-IN-25 is a selective inhibitor of the Colony Stimulating Factor 1 Receptor (CSF1R). This compound demonstrates significant potential in modulating biological processes related to cancer, inflammation, and neurodegeneration. It serves as a valuable tool for researchers investigating the therapeutic implications of CSF1R inhibition in these areas. -
CSF1R Inhibitor
CSF1R-IN-19 is a potent inhibitor of the colony-stimulating factor 1 receptor (CSF1R). It modulates the interaction between tumor-associated macrophages and glioma cells, influencing the exchange of inflammatory factors. This compound is significant for cancer research, particularly in understanding the tumor microenvironment and exploring therapeutic strategies targeting CSF1R. -
Axl/Mer/CSF1R Inhibitor
Axl/Mer/CSF1R-IN-1 is an inhibitor of Axl/Mer receptor tyrosine kinases and CSF1R, demonstrating a binding affinity with Kds of less than 0.1 μM. This compound is valuable for research focused on the modulation of signaling pathways related to cancer, inflammation, and immune response. Its ability to precisely inhibit these targets makes it a useful tool in studies investigating the roles of Axl, Mer, and CSF1R in various biological processes. -
CSF-1R Inhibitor
CSF1R-IN-8 is a potent inhibitor of colony-stimulating factor 1 receptor (CSF-1R) with an IC50 of 0.012 μM. This compound exhibits significant biological activity in modulating CSF-1R signaling pathways, which are crucial for monocyte and macrophage differentiation and function. CSF1R-IN-8 is applicable in research focusing on immunology, cancer therapy, and the study of tumor microenvironments. -
CSF1R Inhibitor
CSF1R-IN-13 is a potent inhibitor of the colony stimulating factor 1 receptor (CSF1R). As a crucial growth factor, CSF-1 modulates the development of bone marrow progenitor cells, monocytes, and macrophages, influencing immune response and cancer progression. This compound serves as a valuable research tool for investigating CSF1R's role in cancer therapies and related disease mechanisms. -
CSF-1R Inhibitor
CSF1R-IN-10 is a potent inhibitor of the colony-stimulating factor 1 receptor (CSF-1R) with an IC50 of 0.005 μM. This compound effectively disrupts CSF-1R signaling, which is crucial for the regulation of macrophage proliferation and differentiation. CSF1R-IN-10 is valuable for research applications focusing on inflammatory diseases, cancer, and the immune response, where modulation of macrophage activity is of interest. -
CSF-1R Inhibitor
Edicotinib hydrochloride is a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R), demonstrating an IC50 of 3.2 nM. This compound is brain penetrant and orally bioavailable, showing minimal off-target effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively. Edicotinib hydrochloride effectively limits microglial expansion, attenuating neurodegeneration in preclinical models. Its unique profile offers potential applications in research related to Alzheimer's disease and rheumatoid arthritis. -
CSF1R Inhibitor
CSF1R-IN-21 is a potent inhibitor of the colony-stimulating factor 1 receptor (CSF1R) with an IC50 value of 31 nM. This compound effectively inhibits CSF1R auto-phosphorylation, making it a valuable tool for investigating the role of CSF1R in neurodegenerative diseases. CSF1R-IN-21 can be utilized in research studies aimed at understanding the molecular mechanisms underlying these conditions and exploring potential therapeutic interventions. -
CSF1R Inhibitor
CSF1R-IN-6 is a potent inhibitor of the colony-stimulating factor 1 receptor (CSF1R), which plays a critical role in regulating macrophage survival and differentiation through the CSF-1/CSF1R signaling pathway. This compound modulates the exchange of inflammatory mediators between tumor-associated macrophages (TAMs) and glioma cells, contributing to the understanding of tumor microenvironment interactions. CSF1R-IN-6 is a valuable tool for cancer research, particularly in elucidating the mechanisms underlying tumor progression and immune evasion. -
CSF-1R Inhibitor
CSF1R-IN-20 is a potent inhibitor of the colony stimulating factor 1 receptor (CSF-1R), exhibiting an IC50 value of 467 nM. This compound effectively inhibits CSF-1R auto-phosphorylation, thereby interfering with downstream signaling pathways. It is primarily utilized in research applications focused on understanding macrophage biology and associated diseases, including cancer and inflammatory disorders. -
CSF1R Inhibitor
CSF1R-IN-15 is a selective inhibitor of the colony-stimulating factor-1 receptor (CSF1R), a membrane-bound tyrosine kinase primarily expressed in macrophages. This compound disrupts CSF1R signaling, which is essential for macrophage differentiation, proliferation, and survival, by targeting its interaction with colony-stimulating factor-1 (CSF-1) and interleukin-34. CSF1R-IN-15 is valuable for research applications focused on macrophage biology and associated pathologies, including cancer, inflammation, and autoimmune diseases. -
CSF Inducer
Leustroducsin B is identified as a colony-stimulating factor (CSF) inducer, primarily targeting bone marrow stromal cells. It effectively stimulates the production of CSF, which plays a critical role in hematopoiesis and immune responses. This compound is valuable for research applications focusing on hematopoietic cell differentiation and the modulation of the bone marrow microenvironment. -
CSF Inducer
Leustroducsin A is a colony-stimulating factor (CSF) inducer that stimulates the production of CSF from bone marrow stromal cells. This compound is essential for research applications focused on hematopoiesis and immune response modulation. Its activity makes it a valuable tool for studying the regulation of blood cell production and potential therapeutic interventions in hematologic disorders. -
CSF Inducer
Leustroducsin C is a colony-stimulating factor (CSF) inducer that stimulates the production of CSF from bone marrow stromal cells. This compound plays a critical role in hematopoiesis by enhancing the proliferation and differentiation of blood cell lineages, making it useful for research applications in immunology and regenerative medicine. Its ability to modulate the bone marrow microenvironment can be leveraged for studies on cellular interactions and therapeutic responses in various hematological conditions. -
IGF-1 Analog
IGF-1 DES is an analog of Insulin-like Growth Factor 1 (IGF-1) with a modified sequence of 83 amino acids. This peptide retains the ability to stimulate DNA synthesis, promoting follicle growth similarly to native IGF-1. It demonstrates comparable biological activity in proliferation assays, such as those conducted using NIH-3T3 cells, making it a valuable tool for research in cellular growth and development. -
IGFBP Inhibitor
NBI-31772 is a non-selective inhibitor of insulin-like growth factor binding proteins (IGFBPs) with a Ki value of 47 nM. This compound exhibits neuroprotective properties and significantly reduces infarct volume during cerebral ischemia. Additionally, NBI-31772 enhances proteoglycan synthesis in osteoarticular chondrocytes and has been shown to amplify the effects of IGF3 on oocyte maturation in zebrafish. Its diverse biological activities make it a valuable tool for research in neuroprotection and chondrocyte biology. -
IGF-I Receptor Inhibitor
JB-1 is a selective inhibitor of the IGF-I receptor, specifically designed to compete with IGF-I for binding at the IGF-1R site, without affecting IGF-II. This compound effectively blocks receptor autophosphorylation, leading to an increase in soluble VEGFR-1 levels. JB-1 demonstrates significant efficacy in normalizing retinal abnormalities, particularly in the context of reducing retinal neovascularization. Its application is particularly relevant for research focused on oxygen-induced retinopathy. -
IGF-I Fragment
IGF-I (24-41) is a fragment derived from the Insulin-like Growth Factor I, encompassing amino acids 24 to 41. This peptide plays a critical role in mediating the biological effects of IGF-I, particularly in neuronal and glial cell support. IGF-I exhibits a range of biological activities, including anabolic, antioxidant, anti-inflammatory, and cytoprotective effects, making IGF-I (24-41) valuable for research in growth regulation and behavioral development studies. -
IGF-1 Receptor Kinase Inhibitor
AG 538 is a potent competitive inhibitor of the IGF-1 receptor kinase, with an IC50 value of 400 nM. This compound effectively blocks IGF-1 signaling pathways, which play a critical role in cell proliferation and survival. Due to its inhibitory action, AG 538 is valuable in research applications investigating cancer growth, metabolic diseases, and other conditions linked to dysregulated IGF-1 signaling. -
IGF-1R Inhibitor
IGF-1R inhibitor-2 is an inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). This compound downregulates IGF-1R activity, which can reverse the transformed phenotype of tumor cells, thereby increasing their susceptibility to apoptosis. It is valuable for research applications focused on cancer biology and therapeutic strategies targeting IGF signaling pathways. -
Recombinant Human IGF-I
Mecasermin is a recombinant form of human insulin-like growth factor I (IGF-I). It primarily targets the IGF receptor and is involved in promoting cell growth and development. This compound is particularly valuable in research focused on growth disorders resulting from growth hormone insensitivity, such as those caused by defects in the growth hormone receptor or the presence of growth hormone-inhibiting antibodies. -
IGF-1R/PI5P4Kα Inhibitor
I-OMe-Tyrphostin AG 538 is a selective inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. This compound effectively disrupts IGF-1R-mediated signaling pathways and demonstrates preferential cytotoxicity towards nutrient-deprived PANC1 cells. Additionally, I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), exhibiting an IC50 value of 1 μM. It is valuable for research applications focused on cancer biology and metabolic stress responses. -
IGF-1R/SRC Inhibitor
IGF-1R/SRC-IN-1 is a selective inhibitor targeting insulin-like growth factor 1 receptor (IGF-1R) and SRC. This compound demonstrates an IC50 value of 63 μM for IGF-1R, making it a valuable tool in the study of signal transduction pathways involved in cancer and metabolic disorders. Its application extends to evaluating the role of IGF-1R and SRC in cellular proliferation, differentiation, and survival, providing insights into potential therapeutic interventions for related diseases. -
IGF-IR Inhibitor
AZ12253801 is an ATP-competitive inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), demonstrating approximately 10-fold selectivity over the insulin receptor. It exhibits potent inhibition of IGF-1R-mediated proliferation in 3T3 mouse fibroblasts transfected with human IGF-1R, with an IC50 value of 17 nmol/L. Additionally, AZ12253801 shows reduced activity against epidermal growth factor receptor (EGFR)-driven proliferation, with an IC50 of 440 nmol/L. Its characteristics make it a valuable tool for investigating anti-tumor mechanisms and IGF-1R signaling pathways in cancer research. -
IGF-1R synthesis reducer
Cibrigirsen is an antisense oligonucleotide that specifically targets and reduces the expression of the insulin-like growth factor I receptor (IGF-1R). By inhibiting IGF-1R synthesis, it plays a crucial role in modulating signaling pathways associated with cell proliferation and survival. This reagent is valuable for research applications focused on cancer biology, particularly in studies investigating the role of IGF-1R in tumor growth and resistance to therapy.
